TITLE: Temporal Changes in FLT3-ITD Regulation of Stem Cell Self-Renewal and Leukemogenesis

PRINCIPAL INVESTIGATOR: Jeffrey Magee

CONTRACTING ORGANIZATION: Washington University
ST. Louis, MO 63110

REPORT DATE: November 2016

TYPE OF REPORT: Final report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Temporal Changes in FLT3-ITD Regulation of Stem Cell Self-Renewal and Leukemogenesis

My goal is to understand how mechanisms that regulate normal hematopoietic development can also influence the mutation spectra of pediatric and adult acute myeloid leukemia (AML). Genetic differences between pediatric and adult AML may underlie differences in outcomes and necessitate different treatment strategies, yet we have few insights into why these differences occur. To address this problem, we are testing whether one mutation, FLT3-ITD, differentially regulates fetal and adult progenitors. FLT3-ITD mutations are more common in adult AML than in childhood AML, and our studies to date have shown that it has age-specific phenotypes. In adult mice, FLT3-ITD depleted the hematopoietic stem cell (HSC) pool and expanded myeloid progenitor populations. These phenotypes were not evident in fetal mice, even in the presence of a collaborating Runx1 mutation. To understand why fetal and adult progenitors responded differently to FLT3-ITD, we characterized signal transduction (e.g. STAT5 and MAPK pathways) in fetal, neonatal and adult progenitors. STAT5 was activated by FLT3-ITD at all stages of development, but MAPK was activated only in post-natal progenitors. Furthermore, STAT5 target gene regulation changed through the course of development. We are now testing whether reactivation of fetal gene products can suppress leukemogenesis. Reprogramming therapies may offer a novel approach for treating AML.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Introduction</td>
<td>4</td>
</tr>
<tr>
<td>2. Keywords</td>
<td>4</td>
</tr>
<tr>
<td>3. Accomplishments</td>
<td>4-5</td>
</tr>
<tr>
<td>4. Impact</td>
<td>5</td>
</tr>
<tr>
<td>5. Changes/Problems</td>
<td>6</td>
</tr>
<tr>
<td>6. Products</td>
<td>6-7</td>
</tr>
<tr>
<td>7. Participants &amp; Other Collaborating Organizations</td>
<td>7-9</td>
</tr>
<tr>
<td>8. Special Reporting Requirements</td>
<td>9</td>
</tr>
<tr>
<td>9. Appendices</td>
<td>10-76</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

The goal of this project is to understand why FLT3-Internal Tandem Duplication (FLT3-ITD) mutations cause acute myeloid leukemia (AML) more frequently in adults than in children. FLT3-ITD encodes a constitutively active FLT3 tyrosine kinase. This mutation occurs in ~30% of adult AML, but only 5-10% of pediatric AML and <1% of infant AML. This suggests that the mutation preferentially transforms older progenitors. To test whether FLT3-ITD has age-specific effects on hematopoietic stem cells (HSCs) and other hematopoietic progenitors, we characterized its function in fetal, neonatal and adult mouse HSCs. We discovered that FLT3-ITD selectively alters the fate of adult, but not fetal progenitors, primarily due to normal temporal changes in transcriptional regulation that make adult progenitors competent to express FLT3-ITD target genes.

2. KEYWORDS

- Flt3-Internal Tandem Duplication (FLT3-ITD)
- Hematopoietic stem cell (HSC)
- Acute myeloid leukemia
- Stat5
- MAP-kinase

3. ACCOMPLISHMENTS

Major goals:

Aim 1: To test whether FLT3-ITD depletes HSCs, expands restricted progenitors and promotes a myeloproliferative neoplasm during the adult, but not fetal stage of development.

Aim 2: To test whether fetal and adult hematopoietic progenitors have different FLT3-ITD driven signal transduction mechanisms and gene expression.

Aim 3: To test whether ectopic Lin28b expression impedes FLT3-ITD driven HSC depletion and leukemogenesis.

Accomplishments under these goals:

Aim 1: To test whether FLT3-ITD depletes HSCs, expands restricted progenitors and promotes a myeloproliferative neoplasm during the adult, but not fetal stage of development.

We completed all of the proposed experiments, and the data are incorporated into a manuscript that was just accepted for publication at eLife (acceptance date 11/21/2016). Please see attached manuscript.

Aim 2: To test whether fetal and adult hematopoietic progenitors have different FLT3-ITD driven signal transduction mechanisms and gene expression.

We completed all of the proposed experiments, and the data are incorporated into a manuscript that was just accepted for publication at eLife (acceptance date 11/21/2016). Please see attached manuscript.
Aim 3: To test whether ectopic Lin28b expression impedes FLT3-ITD driven HSC depletion and leukemogenesis.

We have completed all of the proposed experiments. Ectopic Lin28b expression did not prevent Flt3-ITD driven HSC depletion or leukemogenesis. We are now evaluating other fetal gene products, and we are dissecting the gene regulatory networks that make adult hematopoietic progenitors sensitive to FLT3-ITD.

Opportunities for training and professional development:

This work was selected for an oral presentation at the American Society of Hematology annual meeting (December 2015), and it has formed the basis for an R01 proposal that just received a 5th percentile score (final council review pending). Thus, the work supported by CDMRP has opened new lines of investigation, and funding opportunities, that will sustain my lab for years to come. I received guidance from my primary mentor, Sean Morrison, throughout the funding period.

Dissemination of results to communities of interest:

This work has been presented in oral presentations at the International Society for Stem Cell Research Annual meeting and the American Society of Hematology annual meeting. As noted above, an manuscript describing our results has just been accepted at eLife.

Plans for the next reporting period to accomplish the goals:

Nothing to report.

4. IMPACT

Impact on the development of the principal discipline of the project:

This project provides the first evidence that leukemia causing mutations can have age-specific effects on blood forming stem cells and other immature blood cells. This likely contributes to the differences between pediatric and adult leukemias, and It raises the possibility of targeting developmental programs to suppress leukemogenesis.

Impact on other disciplines:

Nothing to report.

Impact on technology transfer:

Nothing to report.

Impact on society beyond science and technology:

Nothing to report.
5. CHANGES/PROBLEMS:

Changes in approach/reasons:
Nothing to report.

Actual or anticipated problems or delays and actions or plans to resolve them:
Nothing to report.

Changes that had a significant impact on expenditures:
Nothing to report.

Significant changes in the use or care of human subjects:
Nothing to report.

Significant changes in the use or care of vertebrate animals:
Nothing to report.

Significant changes in the use of biohazards and/or select agents:
Nothing to report.

6. PRODUCTS

Publications:
Portern SN, Cluster AS, Yang W, Busken KA, Patel RM, Ryoo J, Magee JA. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations. *eLife* [in press].

Books or one-time publications:
Nothing to report.

Other publications:
Nothing to report.
Websites:
Nothing to report.

Technologies and techniques:
Nothing to report.

Inventions, patent applications or licenses:
Nothing to report.

Other products:
Nothing to report.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

Individuals who have worked on this project:

<table>
<thead>
<tr>
<th>Name:</th>
<th>Jeffrey Magee, M.D., Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project role</td>
<td>PI</td>
</tr>
<tr>
<td>Nearest person month worked</td>
<td>7.2</td>
</tr>
<tr>
<td>Contribution to Project</td>
<td>Dr. Magee oversaw the entire research effort including the design, conduct and interpretation of experiments. He also performs experiments.</td>
</tr>
<tr>
<td>Funding Support - besides DOD</td>
<td>St. Baldrick’s Foundation, Hyundai Hope on Wheels, Gabrielle’s Angel Foundation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Shaina Porter, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project role</td>
<td>Post-doctoral fellow</td>
</tr>
<tr>
<td>Nearest person month worked</td>
<td>12</td>
</tr>
<tr>
<td>Contribution to Project</td>
<td>Dr. Porter designed, conducted and interprets experiments under the guidance of the PI. She has conducted the experiments related to temporal changes in FLT3-ITD regulation of HSCs and the signal transduction and gene expression studies.</td>
</tr>
<tr>
<td>Funding Support</td>
<td>Hyundai Hope on Wheels</td>
</tr>
<tr>
<td>Name:</td>
<td>Andrew Cluster, M.D.</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Project role:</td>
<td>Clinical fellow</td>
</tr>
<tr>
<td>Nearest person month worked</td>
<td>4</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Dr. Cluster characterized the FLT3-ITD; Runx1 compound mutant</td>
</tr>
<tr>
<td>Funding Support besides DOD:</td>
<td>Departmental support for clinical trainees – graduate medical education support.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Jenna Voigtmann</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project role:</td>
<td>Research technician</td>
</tr>
<tr>
<td>Nearest person month worked</td>
<td>6</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Ms. Voigtmann managed the mouse colony and assisted with experiments.</td>
</tr>
<tr>
<td>Funding Support besides DOD:</td>
<td>St. Baldrick’s Foundation and institutional funds.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Kelsey Busken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project role:</td>
<td>Research technician</td>
</tr>
<tr>
<td>Nearest person month worked</td>
<td>6</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Ms. Busken managed the mouse colony and assisted with experiments.</td>
</tr>
<tr>
<td>Funding Support besides DOD:</td>
<td>Hyundai Hope on Wheels, St. Baldrick’s Foundation</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Riddhi Patel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project role:</td>
<td>Research technician</td>
</tr>
<tr>
<td>Nearest person month worked</td>
<td>6</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Ms. Patel co-managed the mouse colony and assisted with experiments.</td>
</tr>
<tr>
<td>Funding Support besides DOD:</td>
<td>Hyundai Hope on Wheels, St. Baldrick’s Foundation</td>
</tr>
<tr>
<td>Name:</td>
<td>Wei Yang</td>
</tr>
<tr>
<td>-----------</td>
<td>----------</td>
</tr>
<tr>
<td>Project role</td>
<td>Bioinformaticist</td>
</tr>
<tr>
<td>Nearest person month worked</td>
<td>0.5</td>
</tr>
<tr>
<td>Contribution to Project</td>
<td>Dr. Wang performed all of the computational work associated with this project – e.g. microarray analyses.</td>
</tr>
<tr>
<td>Funding Support - besides DOD</td>
<td>No grant support – supported by the department of biostatistics</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Jiyeon Ryoo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project role</td>
<td>Research technician</td>
</tr>
<tr>
<td>Nearest person month worked</td>
<td>4</td>
</tr>
<tr>
<td>Contribution to Project</td>
<td>Ms. Ryoo co-managed the mouse colony and assisted with experiments.</td>
</tr>
<tr>
<td>Funding Support - besides DOD</td>
<td>Hyundai Hope on Wheels, St. Baldrick's Foundation</td>
</tr>
</tbody>
</table>

Changes in active other support of the PD/PUI or senior key personnel:

Nothing to report.

Other organizations that were involved as partners:

Nothing to report.

8. SPECIAL REPORTING REQUIREMENTS

Nothing to report.

9. APPENDICES

Please see attached manuscript
Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations

Shaina N. Porter¹, Andrew S. Cluster¹, Wei Yang², Kelsey A. Busken¹,
Riddhi M. Patel¹, Jiyeon Ryoo¹, Jeffrey A. Magee¹,²,³

1. Division of Pediatric Hematology and Oncology, Department of Pediatrics,
Washington University School of Medicine, St. Louis, MO, 63110, USA
2. Department of Genetics, Washington University School of Medicine,
St. Louis, MO, 63110, USA
3. Corresponding author
Department of Pediatrics
Washington University School of Medicine
660 S. Euclid Ave, Box 8220
St. Louis, MO 63110
The FLT3 Internal Tandem Duplication (FLT3\textsuperscript{ITD}) mutation is common in adult acute myeloid leukemia (AML) but rare in early childhood AML. It is not clear why this difference occurs. Here we show that Flt3\textsuperscript{ITD} and cooperating Flt3\textsuperscript{ITD}/Runx1 mutations cause hematopoietic stem cell depletion and myeloid progenitor expansion during adult but not fetal stages of murine development. In adult progenitors, FLT3\textsuperscript{ITD} simultaneously induces self-renewal and myeloid commitment programs via STAT5-dependent and STAT5-independent mechanisms, respectively. While FLT3\textsuperscript{ITD} can activate STAT5 signal transduction prior to birth, this signaling does not alter gene expression until hematopoietic progenitors transition from fetal to adult transcriptional states. Cooperative interactions between Flt3\textsuperscript{ITD} and Runx1 mutations are also blunted in fetal/neonatal progenitors. Fetal/neonatal progenitors may therefore be protected from leukemic transformation because they are not competent to express FLT3\textsuperscript{ITD} target genes. Changes in the transcriptional states of developing hematopoietic progenitors may generally shape the mutation spectra of human leukemias.
Acute myeloid leukemia (AML) can occur at any stage of life yet the mutations that cause AML differ between childhood and adulthood, especially when one compares young children to adults (Chaudhury et al., 2015). For example, \textit{MLL} translocations and \textit{GATA1} mutations are common in infant and early childhood AML but rare in adult AML (Andersson et al., 2015; Horton et al., 2013; Pine et al., 2007). Mutations in \textit{FLT3}, \textit{NPM1}, \textit{DNMT3A}, \textit{TET2} and \textit{IDH1} are all common in adult AML but rare in infant and early childhood AML (Cancer Genome Atlas Research Network, 2013; Ho et al., 2011; Liang et al., 2013; Zwaan et al., 2003). The genetic differences between pediatric and adult AML are not absolute, but they reflect a more general phenomenon in leukemia biology – leukemias in infants, young children, older children and adults have different genetic and epigenetic landscapes, different mechanisms of transformation and different clinical courses (Downing and Shannon, 2002).

Efforts to interpret AML genomes and translate the information into useful therapies will need to account for the influences of age and developmental context on leukemia cell biology. This will require a better understanding of how normal developmental programs shape the process of leukemogenesis.

The mutations that cause AML are thought to accrue first in pre-leukemic hematopoietic stem cells (HSCs) or committed hematopoietic progenitor cells (HPCs) (Jan et al., 2012; Welch et al., 2012), and several properties of these cells change between fetal and adult stages of life: 1) Fetal HSCs divide frequently and retain their self-renewal capacity through cumulative division...
cycles (Pietras and Passegue, 2013). In contrast, adult HSCs are usually quiescent, and self-renewal capacity declines with cumulative divisions (Foudi et al., 2009; Pietras and Passegue, 2013; Wilson et al., 2008). 2) Fetal and adult HSCs have distinct self-renewal mechanisms. For example, Sox17 is required for fetal, but not adult, HSC self-renewal (Kim et al., 2007). Etv6, Ash1l, Mll and Pten are all required for adult, but not fetal, HSC self-renewal (Hock et al., 2004; Jones et al., 2015; Jude et al., 2007; Magee et al., 2012). 3) Fetal and adult HSCs give rise to committed progenitors with distinct epigenetic landscapes (Huang et al., 2016; Xu et al., 2012) and distinct lineage biases (Benz et al., 2012; Copley et al., 2013; Yuan et al., 2012). These observations raise the question of whether mutations can have age-specific effects on gene expression, self-renewal, differentiation and ultimately leukemogenesis. If so, competence for transformation may be a heterochronic property of HSCs and HPCs, and this may explain why pediatric and adult leukemias have different mutations.

The FLT3 Internal Tandem Duplication (FLT3ITD) is an example of an AML driver mutation that occurs more commonly in adults than in young children (30-40% of adult AML, 5-10% of AML in children <10 years old, <1% of infant AML) (Meshinchi et al., 2006). FLT3ITD encodes a constitutively active tyrosine kinase receptor that has been shown to activate the STAT5, MAP-kinase (MAPK), PI3-kinase (PI3K), STAT3 and NF-κB signal transduction pathways in various contexts (Choudhary et al., 2007; Gerloff et al., 2015; Radomska et al., 2006). Mice with a targeted Flt3ITD mutation develop myeloproliferative neoplasms (MPN) (Lee et al., 2007; Li et al., 2008), and several other mutations (e.g. Npm1,
Tet2 and Runx1 mutations) cooperate with Flt3<sup>ITD</sup> to drive AML in mice much as in humans (Mead et al., 2013; Mupo et al., 2013; Rau et al., 2014; Shih et al., 2015). In the absence of cooperating mutations, Flt3<sup>ITD</sup> drives adult HSCs into cycle and depletes the HSC pool (Chu et al., 2012). This may explain why FLT3<sup>ITD</sup> mutations occur late in the clonal evolution of human AML – adult HSCs must first acquire mutations that preserve (or ectopically establish) self-renewal capacity in pre-leukemic progenitors – but it also raises the question of why fetal/neonatal HSCs, which have an inherently high self-renewal capacity (He et al., 2009), do not give rise to FLT3<sup>ITD</sup> positive AML more often than is observed.

To better understand how developmental context shapes myeloid leukemogenesis, we characterized the effects of Flt3<sup>ITD</sup> on HSC self-renewal, myelopoiesis, signal transduction and gene expression at several stages of pre- and post-natal development. Flt3<sup>ITD</sup> did not cause HSC depletion or myeloid progenitor expansion until after birth. This was true even in the presence of a cooperating Runx1 loss-of-function mutation. The FLT3<sup>ITD</sup> protein phosphorylated STAT5 during both pre- and post-natal stages of development while it hyper-activated the MAPK pathway only after birth. To our surprise, MAPK inhibition failed to rescue HSC depletion and myeloid progenitor expansion in adult Flt3<sup>ITD</sup> mice, and Stat5a/b deletion greatly exacerbated these phenotypes. FLT3<sup>ITD</sup> target genes, including STAT5 targets, were not induced in fetal HSCs or HPCs despite pre-natal STAT5 phosphorylation. Instead, FLT3<sup>ITD</sup> target gene activation coincided with a normal transition from fetal to adult gene expression that was
evident by two weeks after birth. These temporal changes in FLT3ITD target gene expression were observed even in the setting of a cooperating Runx1 mutation. Our data establish a crucial role for developmental context in the pathogenesis of FLT3ITD-driven AML. Fetal and neonatal progenitors are protected from transformation because they are not competent to express FLT3ITD target genes. This likely explains why FLT3ITD mutations are more common in adults than young children, and it may reflect a more general role for developmental programming in leukemia pathogenesis.

**Results**

*Flt3ITD does not deplete fetal HSCs*

Since FLT3ITD occurs more commonly in adult AML patients than in young children, we hypothesized that it might have age-specific effects on self-renewal and myelopoiesis. We first tested whether Flt3 expression changes with age. We measured Flt3 transcript expression in CD150+CD48-Lineage-Sca1+c-kit+ HSCs and CD48+Lineage-Sca1+c-kit+ HPCs from 8-10 week old adult and embryonic day (E)14.5 fetal mice by quantitative RT-PCR (qRT-PCR). Flt3 was more highly expressed in HPCs than in HSCs at both ages (Fig. 1A), consistent with prior studies (Buza-Vidas et al., 2011), but its expression did not change with age in either cell population (Fig. 1A). Flow cytometry confirmed that the FLT3 protein is expressed in both fetal and adult progenitors (Fig. 1B).

Since Flt3ITD has previously been shown to deplete adult HSCs (Chu et al., 2012), we tested whether the mutation has a similar effect on fetal HSC
numbers. We measured HSC numbers in 8-10 week old adult bone marrow and E14.5 fetal livers from wild type, \( \text{Flt3}^{\text{ITD}+/} \) and \( \text{Flt3}^{\text{ITD}/\text{ITD}} \) mice. Adult \( \text{Flt3}^{\text{ITD}+/} \) mice had \( \sim 50\% \) fewer HSCs than wild type littermates, consistent with prior studies, and \( \text{Flt3}^{\text{ITD}/\text{ITD}} \) mice had a near-complete loss of phenotypic HSCs (Fig. 1C). HSC depletion in the bone marrow was not accompanied by extramedullary expansion of HSCs in the spleen (Fig. 1E), in contrast to other leukemogenic mutations (e.g. \( Pten \) deletion) that cause depletion of bone marrow HSCs but marked expansion of the spleen HSC population (Magee et al., 2012; Porter et al., 2016). Unlike adult mice, \( \text{Flt3}^{\text{ITD}+/} \) and \( \text{Flt3}^{\text{ITD}/\text{ITD}} \) fetal mice had similar numbers of HSCs as wild type littermates (Fig. 1D). The \( \text{Flt3}^{\text{ITD}} \) mutation therefore depletes adult, but not fetal HSCs.

We next tested whether fetal \( \text{Flt3}^{\text{ITD}/\text{ITD}} \) HSCs are functionally impaired. We performed limiting dilution transplantation assays with either 8-10 week old adult bone marrow cells (600,000, 100,000, 50,000 or 10,000 CD45.2 donor cells competed with 300,000 CD45.1 adult bone marrow cells) or E14.5 fetal liver cells (100,000, 50,000 or 10,000 CD45.2 donor cells competed with 300,000 CD45.1 adult bone marrow cells). Two independent experiments were performed, and fetal and adult donor cells were transplanted at the same time in each experiment. Multi-lineage reconstitution was assessed every 4 weeks for 16 weeks following the transplants, and functional HSC frequencies were calculated by Extreme Limiting Dilution Analysis (Hu and Smyth, 2009). Adult \( \text{Flt3}^{\text{ITD}/\text{ITD}} \) bone marrow had significantly fewer functional HSCs than adult wild type bone marrow.
In contrast, wild type and Flt3\textsuperscript{ITD/ITD} fetal livers had similar HSC frequencies (Fig. 1G).

Our findings raised the question of whether fetal Flt3\textsuperscript{ITD/ITD} HSCs can mature and become depleted after transplantation into adult recipient mice. To test this, we measured donor HSC chimerism in primary recipients of 100,000 wild type and Flt3\textsuperscript{ITD/ITD} fetal liver cells (from Figure 1G). Donor Flt3\textsuperscript{ITD/ITD} HSCs were significantly depleted in primary recipient mice, but wild type competitor HSCs were not (Fig. 1H). Overall donor bone marrow chimerism was not significantly different between recipients of wild type and Flt3\textsuperscript{ITD/ITD} fetal liver cells (Fig. 1I). Secondary transplants confirmed depletion of Flt3\textsuperscript{ITD/ITD} HSCs in the marrow of primary recipients (Fig. 1J, K). Thus, fetal Flt3\textsuperscript{ITD/ITD} HSCs are functional, but they lose repopulating activity after transplantation into adult recipient mice.

Flt3\textsuperscript{ITD} causes HSC depletion and myeloid progenitor expansion by 2 weeks after birth in mice

We next sought to define the age at which Flt3\textsuperscript{ITD} begins to deplete HSCs and expand myeloid progenitor populations. We measured HSCs, HPCs and granulocyte-monocyte progenitor (GMP) numbers at E14.5, E16.5, post-natal day (P)0 and P14. Flt3\textsuperscript{ITD/+} and Flt3\textsuperscript{ITD/ITD} mice had normal HSC numbers at all ages prior to birth (Fig. 2A). HSC depletion was evident at P14 in both the bone marrow and the spleen, though not to the extent observed in adult bone marrow (Fig. 2B). We observed a modest increase in Flt3\textsuperscript{ITD/+} and Flt3\textsuperscript{ITD/ITD} HPCs and
GMPs at P0 (Fig. 2C, E), and this phenotype became more severe, particularly in
Flt3\textsuperscript{ITD/ITD} mice, by P14 (Fig. 2D, E). Spleen enlargement due to MPN was evident
by P14 in Flt3\textsuperscript{ITD/+} and Flt3\textsuperscript{ITD/ITD} mice, but E14.5, E16.5 and P0 liver sizes were
not increased relative to wild type littermates (Fig. 2F). These data show that
Flt3\textsuperscript{ITD} causes HSC depletion, HPC/GMP expansion and MPN beginning at or
shortly after birth.

\textit{FLT3}\textsuperscript{ITD} mutations usually occur late during the clonal evolution of human
AML. This raises the question of whether fetal/neonatal Flt3\textsuperscript{ITD} mice can exhibit
HSC depletion and HPC/GMP expansion when a cooperating mutation is
present. To test this, we analyzed HSC, HPC and GMP frequencies in Flt3\textsuperscript{ITD/+};
Runx1\textsuperscript{f/+}; Vav1-Cre mice. Both mono- and bi-allelic RUNX1 loss-of-function
mutations co-occur with FLT3\textsuperscript{ITD} in human AML (Schnittger et al., 2011), and
Runx1 deletions synergize with Flt3\textsuperscript{ITD} to cause AML in mice (Mead et al., 2013).
For the purposes of these studies we focused on mono-allelic Runx1 deletions
because bi-allelic deletions severely depleted phenotypic HSCs irrespective of
the Flt3 genotype (data not shown). These effects were likely due to previously
described, Runx1-dependent changes in CD48 expression (Cai et al., 2011).

We evaluated HSC, HPC and GMP frequencies in 1) Flt3\textsuperscript{+/+}; Runx1\textsuperscript{f/+} or
Runx1\textsuperscript{f/+}; Cre-negative (control), 2) Flt3\textsuperscript{ITD/+}; Runx1\textsuperscript{f/+} or Runx1\textsuperscript{f/+}; Cre-negative
(Flt3\textsuperscript{ITD/+}), 3) Flt3\textsuperscript{+/+}; Runx1\textsuperscript{f/+}; Vav1-Cre (Runx1\textsuperscript{Δ/+}) and 4) Flt3\textsuperscript{ITD/+}; Runx1\textsuperscript{f/+}; Vav1-
Cre (Flt3\textsuperscript{ITD/+}; Runx1\textsuperscript{Δ/+}) littermates at E14.5, P0, P14 and P21. HSCs were
severely depleted in P14 and P21 Flt3\textsuperscript{ITD/+}; Runx1\textsuperscript{Δ/+} mice relative to controls and
single mutant mice (Fig. 3C, D). In contrast, all four genotypes of mice had
similar HSC frequencies at P0 (Fig. 3B), and Runx1 heterozygosity increased HSC frequency at E14.5 irrespective of the Flt3 genotype (Fig. 3A). HPCs and GMPs were markedly expanded in P14 and P21 Flt3ITD/+; Runx1Δ/+ mice (Fig. 3G, H, K, L). These populations were only modestly expanded in compound mutant mice at P0 (Fig. 3F, J), and they were not expanded at all at E14.5 (Fig. 3E, I).

We next tested whether compound Flt3ITD and Runx1 mutations had age-specific effects on HSC/HPC function. We transplanted 100,000 P0 liver cells or P21 bone marrow cells from control or Flt3ITD/+; Runx1Δ/+ littermate donors, along with 300,000 wild type competitor cells, into irradiated CD45.1 recipient mice. At 2 weeks after the transplants, we observed CD45.2+ donor-derived leukocytes in the peripheral blood of all recipients, irrespective of donor age or genotype (Fig. 3M, N). At 4 weeks after the transplants, donor chimerism was significantly and dramatically reduced in recipients of Flt3ITD/+; Runx1Δ/+ P21 donor cells as compared to recipients of control P21 donor cells and Flt3ITD/+; Runx1Δ/+ P0 donor cells (Fig. 3M). Indeed, only 1 of 15 recipients of Flt3ITD/+; Runx1Δ/+ P21 donor cells had multi-lineage donor chimerism (>0.5% CD45.2+ myeloid and lymphoid cells) (Fig. 3O). In contrast, all recipients of control and Flt3ITD/+; Runx1Δ/+ P0 donor cells had multi-lineage donor chimerism (Fig. 3O). These differences were evident even when we focused specifically on myeloid chimerism (Fig. 3N, P), so they were not simply a reflection of altered lineage biases in the Flt3ITD/+; Runx1Δ/+ progenitors. Altogether, these data show that Flt3ITD has developmental context-specific effects on HSC depletion, myeloid progenitor expansion and repopulating activity, even when paired with a cooperating Runx1 mutation.
Flt3ITD activates STAT5 and MAPK signal transduction pathways in adult HSCs and HPCs, yet it only activates STAT5 in fetal HSCs.

To better understand why Flt3ITD has developmental context-specific effects on HSCs and HPCs, we sought to better characterize the pathways that mediate FLT3ITD signal transduction in vivo. We isolated 25,000 HSC/multipotent progenitors (HSC/MPPs; CD48-Lineage^Sca1^c-kit^+) HPCs and GMPs from adult mice by flow cytometry, and we performed Western blots to assess phosphorylation of STAT5, STAT3, ERK1/2 (a MAPK pathway protein) and AKT (a PI3K pathway protein). Both STAT5 and ERK1/2 were hyper-phosphorylated in Flt3ITD HSC/MPPs and HPCs, as well as in adult Flt3ITD; Runx1^Δ/Δ^ AML cells (Fig. 4A-C). In contrast, STAT3 and AKT were not hyper-phosphorylated in Flt3ITD mutant HSC/MPPs or HPCs (Fig. 4A and Fig. 4 – figure supplement 1A), and Rictor deletion (PI3K/mTORC2 pathway inactivation) did not rescue Flt3ITD-driven HSC depletion or MPN (Fig. 4 – figure supplement 1B, C). These findings suggest that the STAT5 and MAPK pathways mediate FLT3ITD signal transduction in hematopoietic progenitors, but the STAT3 and PI3K pathways do not.

We next tested whether FLT3ITD signal transduction changes between fetal and adult stages of development. We isolated HSC/MPPs and HPCs from wild type and Flt3ITD mice at E14.5, P0, P14 and 8 weeks after birth. We performed Western blots to assess STAT5 and ERK1/2 phosphorylation. STAT5 was hyper-phosphorylated in Flt3ITD mutant HSC/MPPs and HPCs at all stages.
of development, though the degree of STAT5 phosphorylation appeared to increase with age (Fig. 4D, E). ERK1/2 was only hyper-phosphorylated in post-natal Flt3ITD mutant HSC/MPPs and HPCs (Fig. 4D, F). Several other signal transduction proteins, including STAT3, AKT, ribosomal protein S6, p38 and JNK, were not hyper-phosphorylated in Flt3ITD HSC/MPPs or HPCs at any age tested, or their phosphorylation was undetectable (data not shown). Our data reinforce other studies that have implicated STAT5 and MAPK as key downstream effectors of FLT3ITD signaling (Choudhary et al., 2007; Radomska et al., 2006). However, the data suggest that these pathways are not coupled – STAT5 is phosphorylated in fetal progenitors without concurrent MAPK pathway activation. This raises the question of whether each pathway has unique functions downstream of FLT3ITD.

MAPK pathway inhibition has little to no effect on Flt3ITD-driven HSC depletion, HPC expansion and GMP expansion.

We used the MEK inhibitor PD0325901 to test whether MAPK pathway inhibition could prevent HSC depletion and HPC/GMP expansion in Flt3ITD mice. We administered vehicle or PD0325901 to 6-week-old wild type and Flt3ITD/+ mice (5 mg/kg per day for 10 days). This regimen effectively inhibited ERK1/2 phosphorylation in HPCs without affecting STAT5 phosphorylation (Fig. 5 – figure supplement 1). PD0325901-treated wild type mice had significantly more phenotypic HSCs and HPCs than vehicle treated controls (Fig. 5A, B). However, PD0325901 had no effect on HSC numbers, HPC numbers or GMP frequencies.
in Flt3\textsuperscript{ITD/+} mice (Fig. 5A-C). This suggests that sustained MAPK pathway signaling is not required for HSC depletion, HPC expansion and GMP expansion in Flt3\textsuperscript{ITD/+} adult mice.

We next tested whether PD0325901 could prevent the onset of the HSC depletion, HPC expansion and GMP expansion phenotypes if it was given shortly after birth. We treated nursing mothers of wild type, Flt3\textsuperscript{ITD/+} and Flt3\textsuperscript{ITD/ITD} neonates with PD0325901 (5 mg/kg per day) beginning at P1. While this regimen has previously been shown to rescue MAPK pathway-dependent developmental abnormalities in Nf1 mutant neonates (Wang et al., 2012), it did not prevent HSC depletion or HPC expansion in Flt3\textsuperscript{ITD} mutant neonates (Fig. 5D, E), and it only partially rescued GMP expansion (Fig. 5F). Altogether, the data suggest that the MAPK pathway has only a minor role, if any, in causing these phenotypes.

Temporal changes in MAPK pathway regulation are unlikely to account for the different effects of FLT3\textsuperscript{ITD} on fetal and adult progenitors.

STAT5 inactivation exacerbates HSC depletion, HPC expansion, GMP expansion and MPN.

STAT5 has been implicated as a key downstream effector of FLT3\textsuperscript{ITD} in many different systems, and it is hyper-phosphorylated in Flt3\textsuperscript{ITD/+} HSCs and HPCs during fetal, neonatal and adult stages of development (Fig. 4E, F). This raised the question of whether genetic inactivation of Stat5a and Stat5b – with a conditional Stat5a/b allele (Wang et al., 2009) – could prevent HSC depletion, HPC expansion, GMP expansion and MPN in Flt3\textsuperscript{ITD/+} mice. To answer this
question, we evaluated HSCs, HPCs, GMPs and spleen weights in 1) Flt3+/+;
Stat5a/b+/+ or Stat5a/b+/f, Cre− (control), 2) Flt3+/+; Stat5a/b+/+; Mx1-Cre (Stat5Δ/+),
3) Flt3+/+; Stat5a/b+/f, Mx1-Cre (Stat5Δ/Δ), 4) Flt3ITD/+, Stat5a/b+/+ or Stat5a/b+/f, Cre−
(Flt3ITD/+), 5) Flt3ITD/+, Stat5a/b+/f, Mx1-Cre (Flt3ITD; Stat5Δ/+), and 6) Flt3ITD/+
Stat5a/b+/f; Mx1-Cre (Flt3ITD; Stat5Δ/Δ) mice. The mice were treated with poly-
inosine:poly-cytosine (pIpC) beginning at 6 weeks after birth to delete Stat5a/b,
and they were analyzed 4 weeks later. Western blotting confirmed complete loss
of STAT5 protein, and MAPK pathway activation was unaffected by Stat5a/b
deletion (Fig. 6 – figure supplement 1). Surprisingly, Stat5a/b deletion
exacerbated the HSC depletion, HPC expansion and GMP expansion
phenotypes of Flt3ITD/+ mice rather than rescuing them (Fig. 6A-C). Spleen
weights were also enlarged in Flt3ITD; Stat5Δ/+ and Flt3ITD/+; Stat5Δ/Δ mice relative
to control, Stat5Δ/+, Stat5Δ/Δ and Flt3ITD/+ littermates (Fig. 5D). Similar results were
observed when we deleted a single Stat5a/b with Vav1-cre. Only one Stat5a/b
allele was deleted in these analyses because bi-allelic deletion impairs fetal
erthropoiesis (Zhu et al., 2008). Nevertheless, Flt3ITD/+; Stat5a/b+/f; Vav1-Cre
mice had fewer HSCs, more HPCs, more GMPs and larger spleens than control
or Flt3ITD/+ littermates at 8-10 weeks after birth (Fig. 6E-H).

The data reveal an unanticipated function for STAT5 in pre-leukemic,
Flt3ITD-mutant progenitors. They suggest that STAT5 helps to maintain Flt3ITD-
mutant HSCs in an uncommitted state and that it antagonizes Flt3ITD-driven
expansion of more committed myeloid progenitor populations. Thus, FLT3ITD may
simultaneously potentiate self-renewal and myeloid commitment programs via

STAT5-dependent and STAT5-independent pathways, respectively (Fig. 6I).

FLT3\textsuperscript{ITD} activates self-renewal programs in HPCs via STAT5, and it activates

commitment programs independently of STAT5. The changes in HSC and

HPC frequencies in Flt3\textsuperscript{ITD}; Stat5\textsuperscript{a/b} compound mutant mice raise the question of

whether FLT3\textsuperscript{ITD} has STAT5-dependent and STAT5-independent effects on gene

expression, and whether transcriptional changes are developmental context-
specific. To answer these questions we performed two independent experiments
to characterize global changes in gene expression (Fig. 7A). In the first
experiment, we analyzed gene expression in wild type and Flt3\textsuperscript{ITD/+} HSCs and
HPCs at E14.5, P0, P14 and 8-10 weeks after birth. This experiment was meant
to elucidate changes in FLT3\textsuperscript{ITD} target genes over time. In the second
experiment, we analyzed gene expression in adult HPCs from 1) wild type, 2)
Flt3\textsuperscript{ITD/+}, 3) Flt3\textsuperscript{ITD/ITD}, 4) Flt3\textsuperscript{ITD}; Stat5\textsuperscript{Δ/+} and 5) Flt3\textsuperscript{ITD/+}; Stat5\textsuperscript{Δ/Δ} mice. This
experiment was meant to delineate which FLT3\textsuperscript{ITD} targets are STAT5-dependent
and which are STAT5-independent.

We analyzed the data from each experiment independently, and we
merged the data to identify a list of genes that were significantly, differentially
expressed in FLT3\textsuperscript{ITD} progenitors in both experiments. In experiment 1, we
identified 254 annotated coding genes that were differentially expressed between
wild type and Flt3\textsuperscript{ITD/+} HPCs at one or more time points (Fig. 7 – source data
table 1; adjusted p<0.05; fold change ≥2). We did not identify any genes that met
these stringent filtering criteria in HSCs, though statistically significant changes in
gene expression were observed when specific target genes (from the HPC list)
were individually interrogated (p<0.05, Fig. 7 – source data table 1). The
differences between HSCs and HPCs may simply reflect differences in Flt3
expression (Fig. 1A), though it is also possible that HSCs with the strongest
transcriptional responses to FLT3ITD were not captured in our microarray assays
because they differentiated. Of the 254 genes that were differentially expressed
in experiment 1, 58 unique genes were also differentially expressed between wild
type and Flt3ITD/ HPCs in experiment 2 (Fig. 7B and Fig. 7 – figure supplement
1). Thirty-three genes were expressed at higher levels in Flt3ITD HPCs relative to
wild type HPCs, and 25 genes were expressed at lower levels (Fig. 7B). Of
these, 35 normalized when Stat5a/b was deleted, but 23 did not. FLT3ITD
therefore has both STAT5-dependent and STAT5-independent effects on gene
expression, and these effects are more pronounced in HPCs as compared to
HSCs.

We tested whether FLT3ITD activates self-renewal- and commitment-
related transcriptional programs via STAT5-dependent and STAT5-independent
mechanisms, respectively, as predicted by our phenotypic assays (Fig. 6). We
generated self-renewal-related and commitment-related gene sets by comparing
wild type HSCs and HPCs using the data collected in experiment 1 (Figure 7 –
source data table 2). We then used Gene Set Enrichment Analysis (GSEA) to
compare wild type, Flt3ITD/+ and Flt3ITD/++; Stat5Δ/Δ HPCs using data collected in
experiment 2 (Subramanian et al., 2005). Self-renewal-related genes were
enriched in \textit{Flt3}^{ITD/+} HPCs, and commitment-related genes were enriched in wild
366 type HPCs (Fig. 7C). This suggests that the FLT3\textsuperscript{ITD} protein can activate self-
367 renewal mechanisms in otherwise non-self-renewing HPCs. Remarkably, these
368 effects were strongly reversed when \textit{Stat5a/b} was deleted (Fig. 7C). A separately
369 curated self-renewal gene set from Ivanova et al. was similarly enriched in wild
370 type and \textit{Flt3}^{ITD/+} HPCs as compared to \textit{Flt3}^{ITD/+}; \textit{Stat5}^{Δ/Δ} HPCs (Fig. 7D)
371 (Ivanova et al., 2002). These findings are consistent with a model in which
372 FLT3\textsuperscript{ITD} signals via STAT5 to ectopically activate self-renewal programs in HPCs,
373 and it simultaneously promotes myeloid commitment via STAT5-independent
374 mechanisms.

To better understand the STAT5-independent mechanisms that promote
375 myeloid commitment, we performed GSEA on \textit{Flt3}^{ITD/+} and \textit{Flt3}^{ITD/+}; \textit{Stat5}^{Δ/Δ}
376 HPCs with curated gene sets in the MSigDB database (Subramanian et al.,
377 2005). The most significantly enriched gene sets in \textit{Flt3}^{ITD/+}; \textit{Stat5}^{Δ/Δ} HPCs were
378 generally associated with increased inflammatory cytokine signaling (Fig. 7E).
379 This finding is intriguing because several prior studies have linked inflammatory
380 cytokine signaling to loss of adult HSC self-renewal capacity and myeloid
381 differentiation (Baldridge et al., 2010; Essers et al., 2009; Pietras et al., 2016). Of
382 note, we did not observe changes in STAT1, STAT3 or AKT phosphorylation in
383 \textit{Flt3}^{ITD/+}; \textit{Stat5}^{Δ/Δ} HPCs (Fig. 6 – figure supplement 1 and data not shown).
384 Additional studies are still needed to identify the signal transduction molecules
385 that mediate FLT3\textsuperscript{ITD}-driven myeloid commitment, and to test whether changes in

26
cytokine-related gene expression are a cause or a consequence of differentiation in Flt3\textsuperscript{ITD/+}; Stat5\textsuperscript{ΔΔ} HPCs.

FLT3\textsuperscript{ITD}-mediated changes in gene expression correlate temporally with the normal transition from fetal to adult transcriptional programs. FLT3\textsuperscript{ITD} has the capacity to activate functionally relevant signal transduction pathways, such as STAT5, during both pre- and post-natal stages of development (Fig. 4), yet HSC and HPC phenotypes were only observed after birth. This raises the question of whether pre- and post-natal progenitors have distinct transcriptional responses to FLT3\textsuperscript{ITD}. We evaluated FLT3\textsuperscript{ITD} target gene expression in HPCs at E14.5, P0, P14 and adulthood (Fig. 8A). We found that differences between wild type and Flt3\textsuperscript{ITD/+} HPCs were more evident at P14 and adulthood than at E14.5 or P0 (Fig. 8A and Fig. 8 – figure supplement 1). This was true for both STAT5-dependent targets, e.g. Socs2, and STAT5-independent targets, e.g. Ctsg (Fig. 8B). Thus, fetal, neonatal and adult hematopoietic progenitors have distinct transcriptional responses to FLT3\textsuperscript{ITD} signaling.

To better understand when HSCs and HPCs transition from fetal to adult transcriptional programs, we analyzed gene expression in wild type cells from experiment 1. We identified 2627 unique genes (from 3005 different probes) that exhibited significant changes in gene expression in HSCs between E14.5 and adulthood. Of the 228 most differentially expressed transcripts (from the top 250 probes), all followed a consistent trend toward increasing (109 genes) or decreasing (119 genes) expression with increasing age, and most were
differentially expressed in both HSCs and HPCs (Fig. 8C, Fig. 8 – source data table 1). Among these genes were several that encode transcription factors and RNA binding proteins that are known to regulate HSC self-renewal, including *Lin28b, Esr1, Hmga2* and *Egr1* (Fig. 8C, D). Principal component analysis and Euclidean distance measurements showed that P14 HSCs more closely resembled adult HSCs than fetal HSCs, and P0 HSCs more closely resembled fetal HSCs (Fig. 8E). Similar associations were observed for HPCs (Fig. 8 – figure supplement 2). The data show that HSCs and HPCs begin transitioning from fetal to adult transcriptional programs by P14, even before they achieve quiescence (Bowie et al., 2006). Furthermore, the data suggest that HSCs and HPCs become competent to express (or repress) FLT3\(^{ITD}\) target genes as they transition from fetal to adult transcriptional programs.

*Flt3\(^{ITD}\) and Runx1 heterozygous mutations collaboratively induce changes in gene expression in a developmental context-dependent manner*

*Flt3\(^{ITD}\) and Tet2* loss of function mutations have recently been shown to cooperatively induce changes in gene expression and DNA methylation in adult HPCs that are not observed with either mutation alone (Shih et al., 2015). We tested whether *Flt3\(^{ITD}\)* and *Runx1* mutations have similar cooperative effects on transcription and whether the effects are age-specific. We evaluated gene expression in 1) wild type, 2) *Runx1\(^{Δ/+}\)*, 3) *Flt3\(^{ITD/+}\)* and 4) *Flt3\(^{ITD/+}\); Runx1\(^{Δ/+}\)* HPCs at P0 and P14. At P14, we identified 191 genes that were significantly differentially expressed between wild type and *Flt3\(^{ITD/+}\); Runx1\(^{Δ/+}\)* HPCs (adj.
p<0.05; fold change ≥3). At P0 only 8 genes met these criteria, 7 of which overlapped with the P14 gene list (Fig. 9A and Fig. 9 – source data table 1). GSEA showed significant overlap between genes that were differentially expressed in Flt3ITD/+; Runx1Δ/+ HPCs and those that Shih et al. found to be differentially expressed in Flt3ITD; Tet2Δ/Δ HPCs (Shih et al., 2015) (Fig. 9B). This suggests that FLT3ITD can cooperate with diverse mutations to induce a conserved set of target genes.

We used hierarchical clustering to better visualize differences in gene expression at P0 and P14. This approach did show some differences between wild type and Flt3ITD/+; Runx1Δ/+ HPCs at P0 (Fig. 9C), but much greater differences were observed at P14 for most target genes (Fig. 9C, D). Of the 25 most differentially expressed genes in P14 Flt3ITD/+; Runx1Δ/+ HPCs, only three – Nov, Bhlhe40 and Mboat2 – were induced equally at both P0 and P14 (Figs. 9D, Fig. 9 – source data table 1). The remaining genes showed only a partial change in expression at P0 (e.g. Socs2) or no change in expression (e.g. Adgre1, Dusp6, Gem, Postn) (Fig. 9D). GSEA also showed differences in the transcriptional programs of P0 and P14 Flt3ITD/+; Runx1Δ/+ HPCs. Several Gene Ontology and Oncogenic Signatures gene sets were enriched in P14 Flt3ITD/+; Runx1Δ/+ HPCs relative to wild type controls, the most significant of which included genes that are negatively regulated by mTOR (Majumder et al., 2004), genes that inhibit apoptosis (Gene Ontology) and c-myc targets (Bild et al., 2006) (Fig. 9E). These gene sets were not significantly enriched in P0 HSCs with the exception of the anti-apoptotic gene set, which was paradoxically enriched in wild type HPCs.
relative to Flt3\textsuperscript{ITD/+}; Runx1\textsuperscript{A/+} (Fig. 9E). Altogether, the data show that cooperating Flt3\textsuperscript{ITD} and Runx1 mutations – and likely other cooperating mutations – have developmental context-specific effects on gene expression.

**Discussion**

Our data offer a potential explanation for why FLT3\textsuperscript{ITD} mutations are rare in infants and young children with AML. The mutant FLT3\textsuperscript{ITD} protein hyper-activates STAT5 in hematopoietic progenitors during both fetal and adult stages of development, yet its effects on transcription are realized selectively in adult progenitors. Even cooperative interactions between Flt3\textsuperscript{ITD} and Runx1 heterozygous mutations are blunted during fetal and perinatal stages. Thus, FLT3\textsuperscript{ITD} mutations may occur disproportionately in older children and adults with AML because they are less able to activate key effectors of leukemogenesis during earlier stages of life.

Flt3\textsuperscript{ITD} has distinct STAT5-dependent and STAT5-independent effects on self-renewal and myeloid commitment, respectively. In the course of these studies, we discovered that Stat5a/b deletion exacerbates, rather than rescues, the HSC depletion, HPC/GMP expansion and MPN phenotypes of Flt3\textsuperscript{ITD/+} mice. Furthermore, FLT3\textsuperscript{ITD} ectopically activated STAT5-dependent self-renewal programs in HPCs (Fig. 7). These unanticipated findings suggest that FLT3\textsuperscript{ITD} activates both STAT5-dependent and STAT5-independent signal transduction pathways and that these pathways have
opposing effects on self-renewal and myeloid commitment. In this model, STAT5-independent myeloid commitment programs outweigh STAT5-dependent self-renewal programs in Flt3ITD mutant bone marrow so the HSC pool becomes depleted (Fig. 6I and Fig. 7). Stat5a/b deletion can shift the balance further in favor of differentiation, though cooperating mutations may ultimately allow STAT5-dependent self-renewal programs to predominate in transformed AML cells.

The STAT5-independent pathways that antagonize HSC self-renewal and promote myeloid progenitor expansion remain unclear. While the MAPK pathway was hyper-activated in postnatal Flt3ITD/+ HSCs and HPCs, MEK inhibition did not prevent, or even reduce, HSC depletion or HPC expansion in these mice (Fig. 5). Other candidate pathways, including STAT3 and PI3K, were not activated by FLT3ITD (Fig. 4A). It is possible that low levels of signal transduction via these pathways were undetectable by Western blot but nevertheless functionally important. It is also possible that an un-interrogated pathway, such as NF-κB or CDK1 (Gerloff et al., 2015; Radomska et al., 2012), could promote myeloid commitment and antagonize STAT5. Our GSEA data did show increased expression of inflammatory cytokine receptors in Stat5a/b-deficient, Flt3ITD HPCs. This raises the intriguing possibility that inflammatory cytokines could promote differentiation of Flt3ITD mutant progenitors, and perhaps AML cells. Additional genetic studies are needed to resolve whether these transcriptional changes are a cause or a consequence of enhanced lineage commitment in Flt3ITD mutant HPCs.
Developmental programming, re-programming and the origins of pediatric and adult malignancies

Heterochronic genes have been implicated in cancer pathogenesis (Shyh-Chang and Daley, 2013). For example, hepatoblastomas, Wilm’s tumors and most neuroblastomas present early in life, and they often express the oncofetal proteins LIN28 or LIN28B at high levels to help maintain the primitive differentiation states of their respective anlagen (Diskin et al., 2012; Molenaar et al., 2012; Nguyen et al., 2014; Urbach et al., 2014). Adult hepatocellular carcinomas, germ cell tumors and ovarian carcinomas often ectopically activate LIN28 or LIN28B to restore oncofetal programs (Viswanathan et al., 2009). MLL-rearranged leukemias have similarly been shown to express embryonic stem cell-related genes (Somervaille et al., 2009), and BRAFV600E driven melanoma was recently shown to arise from melanocytes that first de-differentiate into primitive neural crest progenitors (Kaufman et al., 2016). In each of these cases, it is easy to appreciate why maintaining or restoring a primitive cell identity might accelerate transformation – fetal cells can proliferate rapidly without differentiating or senescing. However, it is then curious as to why pediatric malignancies are relatively uncommon. Does this simply reflect greater fidelity of the genome at early ages, or are other factors at work?

Our data suggest that the transcriptional regulatory programs of fetal progenitors may, in fact, be protective against some mechanisms of transformation. Fetal and adult progenitors interpret FLT3ITD-derived signals
differently, as evidenced by their distinct transcriptional responses (Figs. 7 and 8), and this constrains the ability of FLT3<sup>ITD</sup> to transform fetal progenitors. Either they lack key transcriptional co-activators, or the epigenetic landscape of fetal progenitors suppresses FLT3<sup>ITD</sup> target gene activation. Further work is needed to understand the cis- and trans-regulatory elements that determine when and how individual mutations are competent to transform. If we can understand how normal developmental programs interact with genetic mutations to cause malignancies, it may be possible to target these interactions therapeutically.

Materials and methods

Mouse strains

The Flt3<sup>ITD</sup> RRID:IMSR_JAX:011112 (Lee et al., 2007), Runx1<sup>f</sup>
RRID:IMSR_JAX:008772 (Taniuchi et al., 2002), Stat5a/b<sup>f</sup>
RRID:MMRRC_032053-JAX (Cui et al., 2004), Rictorf<sup>f</sup> RRID:IMSR_JAX:020649
(Magee et al., 2012), Vav1-Cre RRID:IMSR_JAX:008610 (Siegemund et al., 2015) and Mx1-Cre RRID:IMSR_JAX:003556 (Kuhn et al., 1995) mouse strains have all been previously described and were obtained from The Jackson Laboratory. These lines were all on a pure C57BL/6 background. Expression of Mx1-Cre was induced by three intraperitoneal injections of plpC (GE Life Sciences; 10 µg/dose) over five days beginning 6 weeks after birth. PD0325901 (Cayman Chemicals) was suspended in 0.5% hydroxypropylmethylcellulose vehicle (Sigma) and administered by oral gavage as described in the text. All mice were housed in the Department for Comparative Medicine at Washington
University. All animal procedures were approved by the Washington University Committees on the Use and Care of Animals.

Isolation of HSCs and flow cytometry

Bone marrow cells were obtained by flushing the long bones (tibias and femurs) or by crushing long bones, pelvic bones and vertebrae with a mortar and pestle in calcium and magnesium-free Hank’s buffered salt solution (HBSS), supplemented with 2% heat inactivated bovine serum (Gibco). Splenocytes were obtained by macerating spleens with frosted slides. Single cell suspensions were filtered through a 40 um cell strainer (Fisher). The cells were then stained for 20 minutes with fluorescently conjugated antibodies, washed with HBSS + 2% bovine serum and resuspended for analysis. Cell counts were measured by hemocytometer. The following antibodies were used for flow cytometry, all were from Biolegend except as indicated: CD150 (TC15-12F12.2), CD48 (HM48-1), Sca1 (D7), c-Kit (2B8), Ter119 (Ter-119), CD3 (17A2), CD11b (M1/70), Gr-1 (RB6-8C5), B220 (RA3-6B2), CD8a (53-6.7), CD34 (eBioscience, RAM34), CD2 (RM2-5), CD45.1 (A20), CD45.2 (104), CD127 (A7R340), CD16/32 (93) and FLT3/CD135 (A2F10). Lineage stains for all experiments included CD2, CD3, CD8a, Ter119, B220 and Gr1. Antibodies to CD4 and CD11b were omitted from the lineage stains because they are expressed on fetal HSCs at low levels.

 Unless otherwise indicated, we used the following surface marker phenotypes to define cell populations: HSCs (CD150⁺, CD48⁻Lineage⁻, Sca1⁺, c-kit⁺), HPCs (CD48⁻Lineage⁻, Sca1⁺, c-kit⁺), and GMPs (Lineage⁻, Sca1⁻, CD127⁻, c-kit⁺,
CD34⁺, CD16/32⁺). Non-viable cells were excluded from analyses by 4′,6-
 diamidino-2-phenylindone (DAPI) staining (1 µg/ml). When HSCs and HPCs
 were isolated for Western blotting or RNA collection, c-kit⁺ cells were enriched
 prior to sorting by selection with paramagnetic beads (Miltenyi Biotec). Flow
 cytometry was performed on a BD FACSARia Fusion flow cytometer (BD
 Biosciences).

Limiting dilution long-term repopulation assays

Eight to ten week old C57BL/6Ka-Thy-1.2 (CD45.1) recipient mice were
 given two doses of 550 rad delivered at least 3 hours apart. Donor fetal liver or
 bone marrow cells were mixed with competitor bone marrow cells at the doses
 indicated in the text and injected via the retroorbital sinus. To assess donor
 chimerism, peripheral blood was obtained from the submandibular veins of
 recipient mice at the indicated times after transplantation. Blood was subjected to
 ammonium-chloride lysis of the red blood cells and leukocytes were stained with
 antibodies to CD45.2, CD45.1, B220, CD3, CD11b and Gr-1 to assess
 multilineage engraftment. Functional HSC frequencies were calculated and
 compared by using Extreme Limiting Dilution Analysis (Hu and Smyth, 2009). For
 secondary transplants, mice were injected with 3 million cells from the bone
 marrow of primary recipient mice.

Quantitative RT-PCR

RNA was isolated from HSCs with RNAeasy micro plus columns (Qiagen)
and converted to cDNA with Superscript III reverse transcriptase (Lifetech).
Quantitative RT-PCR assays were performed with Taqman Gene Expression Assays specific to mouse Flt3 and β-actin (Lifetech). Analysis was performed with a Mx3005P qPCR system (Agilent). Samples were normalized based on β-actin expression.

**Western blots**

Twenty-five thousand HSC/MPPs, HPCs or GMPs were double sorted into Trichloracetic acid (TCA), and the volume was adjusted to a final concentration of 10% TCA. Extracts were incubated for 15 minutes on ice and centrifuged at 16,100xg at 4°C for 10 minutes. Precipitates were washed in acetone twice and dried. The pellets were solubilized in 9M urea, 2% Triton X-100, 1% DTT. LDS loading buffer (Lifetech) was added and the pellet was heated at 70°C for 10 minutes. Samples were separated on Bis-Tris polyacrylamide gels (Lifetech) and transferred to PVDF membrane (Lifetech). All antibodies were from Cell Signaling Technologies except as indicated: P-STAT5 (4322), Total STAT5 (9363), P-STAT3 (9145), Total STAT3 (9139), P-ERK1/2 (4370), Total ERK1/2 (4696), P-AKT Ser473 (4060), P-AKT T308 (13038), Total AKT (4691), α-TUBULIN (3873), β-ACTIN (Santa Cruz Bioscience, clone AC-17), HRP-anti-Rabbit IgG (7074) and HRP-anti-mouse IgG (7076). Blots were developed with the SuperSignal West Femto or Pico chemiluminescence kits (Thermo Scientific). Blots were stripped (1% SDS, 25 mM glycine pH 2) prior to re-probing.

**Cytospins**
Bone marrow cells were isolated and spun onto glass slides using a
Shandon Cytospin 3. The slides were stained using Protocol Hema 3 Wright-
Giemsa stain (Fisher Scientific). All slides were reviewed by a pediatric
hematologist (JAM or ASC).

Statistical analysis
In all cases, multiple independent experiments were performed on at least
two different days to verify that the data are reproducible. Grouped data reflect
biological replicates (i.e. independent mice) and are represented by mean +/-
standard deviation. Statistical comparisons between groups were made with the
two-tailed Student’s t-test except as noted in the figure legends. When multiple
genotypes were compared, statistical significance was determined by performing
a one-way ANOVA followed by a Holm-Sidak post-hoc test to correct for multiple
comparisons. For transplantation experiments, the percentages of mice with
multilineage reconstitution were compared with the Fisher’s exact test. All
comparisons were performed with GraphPad Prism 6, RRID:SCR_002798.

Gene expression analysis
Ten thousand HSCs or HPCs were double sorted directly into RLT plus
RNA lysis buffer (Qiagen) and RNA was isolated with RNAeasy micro plus
columns (Qiagen). Transcripts were amplified with the WTA2 kit (Sigma) with the
Kreatech ULS RNA labeling kit (Kreatech Diagnostics). Labeled cDNA was
hybridized to Agilent Mouse 8x60K microarrays and analyzed with an Agilent C-
class scanner. Signal data were assembled and processed in Partek RRID:SCR_011860, and samples were compared by Linear Models for Microarrays, RRID:SCR_010943 (Ritchie et al., 2015; Smyth, 2004). Adjusted p-values were calculated by the Benjamini and Hochberg false discovery rate (Benjamini and Hochberg, 1995). Z-scores were calculated as previously described (Cheadle et al., 2003). Hierarchical cluster analysis was performed with Cluster 3.0 and visualized with Java TreeView; RRID:SCR_013505 and RRID:SCR_013503 (Eisen et al., 1998). Principal component analyses and Euclidean distance comparisons (by permutation testing) were performed with the R software environment. Microarray data sets have been deposited into Gene Expression Omnibus (GSE81153). GSEA was performed using gene sets that were generated as cited in the text, or with gene sets curated in the MSigDB databases; RRID:SCR_003199 (Subramanian et al., 2005).

Acknowledgements

This work was supported by grants from the Department of Defense (CA130124), the St. Baldrick’s Foundation, Hyundai Hope on Wheels, the Gabrielle’s Angel Foundation for Cancer Research and the Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital. JAM is a scholar of the Child Health Research Center for Excellence in Developmental Biology at Washington University (K12-HD076224). ASC is supported by a training grant to the Washington University Department of Pediatrics (5T32HD043010-12). We thank Jenna Voigtmann for technical assistance. We
thank D. Bhattacharya, G. Challen, I. Maillard and R. Signer for comments on the manuscript.
References


a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors. Cell reports 3, 1766-1776.


differential expression in microarray experiments. Statistical applications in
genetics and molecular biology 3, Article3.

Somervaille, T.C., Matheny, C.J., Spencer, G.J., Iwasaki, M., Rinn, J.L., Witten,
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a
transcriptional program shared with embryonic rather than adult stem cells. Cell
Stem Cell 4, 129-140.

Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette,
Gene set enrichment analysis: a knowledge-based approach for interpreting

Taniuchi, I., Osato, M., Egawa, T., Sunshine, M.J., Bae, S.C., Komori, T., Ito, Y.,
and Littman, D.R. (2002). Differential requirements for Runx proteins in CD4
repression and epigenetic silencing during T lymphocyte development. Cell 111,
621-633.

Urbach, A., Yermalovich, A., Zhang, J., Spina, C.S., Zhu, H., Perez-Atayde, A.R.,


Figure Legends

Figure 1. Flt3ITD causes HSC depletion in adult but not fetal mice.

(A) Flt3 transcript expression in fetal and adult HSCs and HPCs relative to fetal HSCs; n=4-9. (B) FLT3 expression in fetal and adult HSC/HPCs (Lineage− Sca1+c-kit+) and unfractionated fetal liver or bone marrow cells, as determined by flow cytometry (N=3). (C) HSC numbers in two tibias and femurs from adult wild type and Flt3ITD mice; n=12-16. (D) HSC numbers in fetal livers from E14.5 wild type and Flt3ITD mice; n=9-20. (E) Spleen HSC frequency in adult wild type and Flt3ITD/ITD mice; n=4-5. (F, G) Limiting dilution analyses using adult bone marrow (F) or E14.5 fetal liver cells (G); n=9-10 recipients per cell dose. Wild type and Flt3ITD/ITD HSC frequencies were calculated by extreme limiting dilution analysis. (H, I) Frequencies of donor (CD45.2) and competitor (CD45.1) HSCs (H) and donor bone marrow cells (I) in primary recipients of 100,000 fetal liver cells; n=15 per genotype. (J) Frequencies of CD45.2+ peripheral blood cells in secondary recipients of donor cells that originated from wild type or Flt3ITD/ITD fetal livers; n=12-14. (K) Percentage of secondary recipient mice with multilineage donor reconstitution. In all panels, error bars indicate standard deviations and n reflects biological replicates. * p<0.05, *** p<0.001 by two-tailed Student’s t-test. ## p<0.01 by Fisher exact probability test.

Figure 2. Flt3ITD causes HSC depletion, HPC expansion and GMP expansion at, or shortly after, birth.
(A) Absolute HSC numbers in fetal or P0 livers for the indicated genotypes. (B) Absolute HSC numbers in P14 and adult bone marrow (2 hind limbs) or P14 spleen. (C, D) Fetal and adult HPC numbers (2 hind limbs). (E) GMP frequencies in fetal liver or adult bone marrow. (F) Liver or spleen weights. In all panels, error bars indicate standard deviations; n=6-20 biological replicates for each age and genotype. * p<0.05; ** p<0.01; *** p<0.001 by two-tailed Student’s t-test relative to the wild type control at the same time point.

Figure 3. $Flt3^{ITD}$ and $Runx1$ mutations cooperate to deplete HSCs and expand committed progenitor populations after birth. (A-D) HSC frequencies in E14.5 fetal liver, P0 liver, P14 bone marrow and P21 bone marrow for the indicated genotypes. (E-H) HPC frequencies in E14.5 fetal liver, P0 liver, P14 bone marrow and P21 bone marrow for the indicated genotypes. (I-L) GMP frequencies in E14.5 fetal liver, P0 liver, P14 bone marrow and P21 bone marrow for the indicated genotypes. (M, N) Percentages of CD45.2$^+$ donor leukocytes (M) or CD11b$^+$Gr1$^+$ myeloid cells (N) in the peripheral blood of recipients of P0 liver or P21 bone marrow cells from control or $Flt3^{ITD/+}; Runx1^{Δ/+}$ mice. Measurements are shown at 2 and 4 weeks after transplantation. (O, P) Percentage of recipients with multi-lineage (O) or myeloid (P) donor reconstitution at 4 weeks after transplantation. In all panels, error bars indicate standard deviations. For A-L, n=8-18 biological replicates per genotype and age. For M-P, n=14-15 recipients from 3 independent donors. Statistical significance was determined with a one-way ANOVA followed by Holm-Sidak’s post-hoc test.
for multiple comparisons (* p<0.05; ** p<0.01; *** p<0.001), or # p<0.0001 by the Fisher exact probability test.

Figure 4. FLT3\textsuperscript{ITD} activates STAT5 in both fetal and adult progenitors, but it activates the MAPK pathway after birth.

(A) Western blot showing phosphorylation of STAT5, ERK1/2, STAT3 and AKT in adult wild type and Flt3\textsuperscript{ITD/+} HSC/MPPs, HPCs and GMPs. (B) Flt3\textsuperscript{ITD/+}; Runx1\textsuperscript{Δ/Δ} progenitors give rise to AML in adult mice (right panel) that is not observed in wild type or Flt3\textsuperscript{ITD/+} bone marrow. Scale bars indicate 100 microns. (C) STAT5 and MAPK are hyper-phosphorylated in Flt3\textsuperscript{ITD/+}; Runx1\textsuperscript{Δ/Δ} AML that develops in adult mice. (D) STAT5 and ERK1/2 phosphorylation in wild type and Flt3\textsuperscript{ITD/+} HSC/MPPs at E14.5, P0, P14 and adulthood. (E) STAT5 phosphorylation in wild type and Flt3\textsuperscript{ITD/+} HPCs at E14.5, P0, P14 and adulthood. (F) ERK1/2 phosphorylation in wild type and Flt3\textsuperscript{ITD/+} HPCs at E14.5, P0, P14 and adulthood. Each blot is representative of 2 (panels A and C) or at least 3 (panels D-F) independent experiments.

Figure 5. MAPK pathway inhibition does not prevent HSC depletion or committed progenitor expansion in Flt3\textsuperscript{ITD/+} mice.

(A-D) HSC numbers (A), HPC numbers (B) and GMP frequencies (C) in wild type and Flt3\textsuperscript{ITD/+} mice that were treated with vehicle or PD0325901 for 10 days beginning at 6 weeks after birth; n=4-5 biological replicates per genotype and treatment. (D-F) HSC numbers (D), HPC numbers (E) and GMP frequencies (F)
in P19 wild type, \textit{Flt}^{\text{ITD/+}} and \textit{Flt}^{\text{ITD/ITD}} mice whose mothers were given PD0325901 beginning at P1; n=4-15 biological replicates for each genotype and treatment. In all panels, error bars indicate standard deviation. Statistical comparisons were made with a two-tailed Student’s t-test. * p<0.05 relative to vehicle treated cells with equivalent genotypes; # p<0.05 relative to similarly treated wild type controls; ^ p<0.05 relative to similarly treated wild type and \textit{Flt}^{\text{ITD/+}} groups.

**Figure 6.** \textit{Stat5a/b} deletion exacerbates rather than rescues HSC depletion, HPC expansion, GMP expansion and MPN in \textit{Flt}^{\text{ITD/+}} mice.

(A-D) HSC numbers (A), HPC numbers (B), GMP frequencies (C) and spleen weights (D) in \textit{Flt}^{\text{ITD/+}; Stat5a/b^{fl/fl}; Mx1-Cre} compound mutant mice and littermate controls; n=6-20 biological replicates per genotype. \textit{Stat5a/b} was conditionally deleted 6 weeks after birth, and this caused a complete loss of protein expression (figure supplement 1). (E-H) HSC numbers (E), HPC numbers (F), GMP frequencies (G) and spleen weights (H) in \textit{Flt}^{\text{ITD/+}; Stat5a/b^{fl/+}; Vav1-Cre} compound mutant mice and littermate controls; n=8-20 biological replicates per genotype. (I) The data suggest that STAT5-dependent pathways promote HSC self-renewal downstream of FLT3\textsuperscript{ITD}, but these effects are outweighed by STAT5-independent myeloid commitment pathways. In all panels, error bars indicate standard deviation. Statistical significance was determined with a one-way ANOVA followed by Holm-Sidak’s post-hoc test for multiple comparisons. *p<0.05; ** p<0.01; *** p<0.001.
**Figure 7.** FLT3\textsuperscript{ITD} activates STAT5-dependent self-renewal programs and STAT5-independent commitment programs.

(A) Overview of experimental design. (B) Heatmap representing genes that were differentially expressed in Flt3\textsuperscript{ITD} mutant HPCs relative to wild type HPCs in both experiments 1 and 2. Each column represents an independent sample. The gene names and dendrogram are shown in figure supplement 1 attached to this figure.

(C) Self-renewal and commitment-related gene sets were generated by identifying genes that were more highly expressed (>5 fold, adj. p<0.05) in HSCs relative to HPCs (self-renewal), or HPCs relative to HSCs (commitment). GSEA plots show ectopic activation of self-renewal-related genes in HPCs that express FLT3\textsuperscript{ITD}, but these effects are reversed in Stat5\textsuperscript{a/b}-deficient HPCs. (D) An independently curated self-renewal gene set (Ivanova et al., 2002) was similarly enriched in wild type and Flt3\textsuperscript{ITD/+} HPCs relative to Flt3\textsuperscript{ITD/+}; Stat5\textsuperscript{Δ/Δ} HPCs. (E) GSEA revealed enrichment of gene sets associated with increased inflammatory cytokine signaling.

**Figure 8.** Flt3\textsuperscript{ITD}-mediated changes in gene expression correlate with the normal transition from fetal to adult transcriptional programs.

(A) Heatmap showing expression of FLT3\textsuperscript{ITD} target genes at E14.5, P0, P14 and adult stages. Each column shows average fold change in Flt3\textsuperscript{ITD/+} HPCs relative wild type HPCs at the indicated time point; n=3-4 independent arrays per genotype. The gene names and dendrogram are shown in figure supplement 1
attached to this figure. (B) Representative examples of expression of STAT5-independent (Ctsg) and STAT5-dependent (Socs2) FLT3<sup>ITD</sup> targets. Error bars reflect standard deviation. ***adj. p<0.05 relative to wild type at the same time point, # adj. p<0.05 relative to Flt3<sup>ITD/+</sup> at the same time point. (C) Heterochronic genes began transitioning from fetal to adult expression patterns between P0 and P14, concordant with sensitivity to FLT3<sup>ITD</sup>. Genes that encode transcription factors and RNA binding proteins are noted to the right of the heatmap. A complete gene list is provided in source data table 1 attached to this figure. (D) Representative examples of heterochronic genes that show decreased (Lin28b) or increased (Esr1; Estrogen Receptor α) expression in adult relative to fetal HSCs and HPCs. Error bars reflect standard deviation. $$$ adj. p<0.05 relative to E14.5 for both HSCs and HPCs. (E) Principal component analysis and Euclidean distance measurements show that gene expression in P0 HSCs more closely resembles fetal HSCs than adult HSCs, and gene expression in P14 HSCs more closely resembles that of adult HSCs. Similar calculations for HPCs are shown in figure supplement 2.

**Figure 9.** Flt3<sup>ITD</sup> and Runx1 mutations cooperatively induce changes in gene expression at P14, yet they have a much smaller effect at P0. (A) Venn diagram showing overlap between genes that were significantly differentially expressed (adj. p<0.05, fold change ≥3) in Flt3<sup>ITD/+</sup>; Runx1<sup>Δ/+</sup> HPCs relative to wild type at P14 or P0; n=4-5 arrays per genotype and age. (B) GSEA shows that differentially expressed genes in Flt3<sup>ITD/+</sup>; Runx1<sup>Δ/+</sup> HPCs overlap
significantly with genes that are differentially expressed in Flt3\textsuperscript{ITD/+}; Tet2\textsuperscript{Δ/Δ} HPCs (Shih et al., 2015). (C) Heatmap showing expression of genes that were differentially expressed in Flt3\textsuperscript{ITD/+}; Runx1\textsuperscript{Δ/+} HPCs relative to wild type HPCs. Each column indicates average fold change relative to the wild type samples from the same time point. The gene list is shown in source data table 1 attached to this figure. (D) Representative examples of genes that are among the most differentially expressed in Flt3\textsuperscript{ITD/+}; Runx1\textsuperscript{Δ/+} HPCs relative to wild type HPCs at P14. Most show much smaller changes in expression at P0. Error bars reflect standard deviations, * adj. p<0.05. (E) GSEA identified several gene sets that were enriched in Flt3\textsuperscript{ITD/+}; Runx1\textsuperscript{Δ/+} HPCs relative to wild type HPCs at P14. Three of the most significantly enriched gene sets are shown for P14 and P0.

**Supplemental Figure Legends**

**Figure 4 – figure supplement 1.** The PI3K/mTORC2 pathway does not mediate HSC depletion or MPN in Flt3\textsuperscript{ITD} mutant mice. (A) Western blot showing STAT5 and AKT phosphorylation in wild type and Flt3\textsuperscript{ITD/ITD} HPCs. Pten-deficient HPCs were included as a positive control for AKT phosphorylation. Rictor deletion prevented AKT hyper-phosphorylation by mTORC2. (B,C) HSC numbers in two tibias and femurs (B) and spleen weights (C) in Flt3\textsuperscript{ITD/ITD}; Rictor\textsuperscript{fl/fl}; Vav1-Cre compound mutant mice (and the indicated controls) after conditional Rictor deletion; n=3-12 per genotype. Error bars indicate standard deviations.
Figure 5 – figure supplement 1. Inhibition of the MAPK pathway fails to rescue FLT3\textsuperscript{ITD}-mediated HSC depletion and myeloid progenitor expansion, but Stat5\textsubscript{a/b} deletion enhances these phenotypes. A Western blot was performed with 25,000 HPCs from wild type and Flt3\textsuperscript{ITD/+}, vehicle and PD0325901 treated mice. PD0325901 inhibited ERK1/2 phosphorylation without affecting STAT5 phosphorylation.

Figure 6 – figure supplement 1. Stat5\textsubscript{a/b} deletion causes a complete loss of phosphorylated and total STAT5 protein. A Western blot was performed with 25,000 HPCs from wild type, Flt3\textsuperscript{ITD/+} and Flt3\textsuperscript{ITD/+}; Stat5\textsuperscript{ΔΔ} adult mice (representative of 2 independent experiments). ERK1/2 phosphorylation was not affected by STAT5 deletion. STAT3 phosphorylation was not affected, and STAT1 and AKT phosphorylation were not detectable (not shown).

Figure 7 – figure supplement 1. FLT3\textsuperscript{ITD} induces STAT5-dependent and STAT5-independent changes in gene expression. An expanded version of Figure 7B with the dendrogram and gene names attached to the heatmap.
Figure 8 – figure supplement 1. FLT3<sup>ITD</sup>-mediated changes in gene expression correlate temporally with a transition from fetal to adult transcriptional states.

An expanded version of Figure 8A with the dendrogram and gene names attached to the heatmap.

Figure 8 – figure supplement 2. HPCs express heterochronic genes and begin to transition from fetal to adult transcriptional programs by P14.

Principal component analysis shows temporal changes in HPC gene expression before and after birth. Euclidean distance measurements and permutation testing show that P0 HPCs more closely resemble fetal HPCs than adult HPCs. P14 HPCs more closely resemble adult HPCs.

Source Data Tables

Figure 7 – source data table 1. Significantly differentially expressed genes in Flt3<sup>ITD/+</sup> HSCs and HPCs. Fold changes are shown for 270 probes that represent 254 differentially expressed genes in Flt3<sup>ITD/+</sup> HPCs relative to controls. HSC fold change data are also shown. P-values and adjusted p-values reflect significance across the entire time course.
Figure 7 – source data table 2. Self-renewal-related and commitment-related gene sets. These gene sets were determined by identifying genes that were more highly expressed in HSCs relative to HPCs (self-renewal) or HPCs relative to HSCs (commitment). In each case, a fold change threshold of 5 and an adjusted p-value threshold of <0.05 were used to define the lists.

Figure 8 – source data table 1. Heterochronic gene expression in wild type HSCs and HPCs. Source data (log2) are shown for the 250 most differentially expressed probes in developing HSCs (228 unique genes).

Figure 9 – source data table 1. Flt3ITD and Runx1 mutations cooperatively induce changes in gene expression in post-natal HPCs. Genes that are differentially expressed (Adjusted p<0.05, fold change ≥3) in Flt3ITD/+; Runx1Δ/+ HPCs at P0 and P14 are shown in the indicated tables.
Figure 1

A. FLT3 expression (MFI)

B. Liver/BM and LSK

C. Adult

D. Fetal

E. Spleen HSCs (%)

F. Adult Donor

G. Fetal Donor

H. HSC frequency (%)

I. Donor BM cells (%)

J. Donor leukocytes (%)

K. multilineage reconstituted (%)
Figure 3
Figure 4

A

<table>
<thead>
<tr>
<th>HSC</th>
<th>HPC</th>
<th>GMP</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-STAT5 (Y694)</td>
<td>Total STAT5</td>
<td>P-STAT3 (Y705)</td>
</tr>
<tr>
<td>+/+</td>
<td>ITD/+</td>
<td>+/+</td>
</tr>
</tbody>
</table>

E14.5 | P0 | P14 | Adult |

β-ACTIN

B

WT | ITD | AML

P-STAT5 (Y694) | Total STAT5 | P-ERK1/2 (T202/Y204) | Total ERK1/2 | α-TUBULIN

ITD/+/ Runx1Δ/Δ

C

HPC | GMP | AML

P-STAT5 (Y694) | Total STAT5 | P-ERK1/2 (T202/Y204) | Total ERK1/2 | α-TUBULIN

ITD/+/ Runx1Δ/Δ

D

HSC/MPPs

P-STAT5 (Y694) | Total STAT5 | P-ERK1/2 (T202/Y204) | Total ERK1/2 | α-TUBULIN

E14.5 | P0 | P14 | Adult

HPCs

P-STAT5 (Y694) | Total STAT5 | P-ERK1/2 (T202/Y204) | Total ERK1/2 | β-ACTIN

F

HPCs

P-ERK1/2 (T202/Y204) | Total ERK1/2 | β-ACTIN
Figure 5

A

HSCs (x1000)

-/+  ITD/+  PD

Flt3 genotype

B

HPCs (x1000)

-/+  ITD/+  PD

Flt3 genotype

C

GMPs (%)

-/+  ITD/+  PD

Flt3 genotype

D

HSCs (x1000)

-/+  ITD/ITD  PD

Flt3 genotype

E

HPCs (x1000)

-/+  ITD/ITD  PD

Flt3 genotype

F

GMPs (%)

-/+  ITD/ITD  PD

Flt3 genotype

Adult

Neonate
Figure 6

A: HSCs (x1000)

B: HPCs (x1000)

C: GMPS (%)

D: Spleen weight (mg)

E: HSCs (x1000)

F: HPCs (x1000)

G: GMPS (%)

H: Spleen weight (mg)

I: Normal

- **STAT5** dependent
- **STAT5** independent

FLT3-ITD; Stat5-null

- **STAT5** independent

**p=0.05**
**Figure 7**

**A**

**Experiment 1**
- Ages: E14.5, P0, P14, and 8-10 week
- Populations: HSC and HPC
- Genotypes: Wild type and Flt3ITD/+ 

**Experiment 2**
- Ages: 8-10 weeks old
- Populations: HPC
- Genotypes: Wild type, Flt3ITD/+, Flt3ITD/ITD, Flt3ITD/+; Stat5Δ/+; Stat5Δ/Δ

**B**
- Heatmap showing expression levels of Flt3 and Stat5 in different genotypes.
  - Increased in Flt3-ITD STAT5 target
  - Increased in Flt3-ITD STAT5 independent
  - Decreased in Flt3-ITD STAT5 target
  - Decreased in Flt3-ITD STAT5 independent

**C**
- WT vs. Flt3ITD/+ 
- P = 0.017, FDR = 0.045, NES = -1.6
- WT vs. Flt3ITD/+; Stat5Δ/Δ 
- P = 0.034, FDR = 0.047, NES = 1.6
- Flt3ITD/+ vs. Flt3ITD/+; Stat5Δ/Δ 
- P = 0.0, FDR = 0.002, NES = 1.9

**D**
- WT vs. Flt3ITD/+ 
- P = 0.002, FDR = 0.003, NES = 1.9
- WT vs. Flt3ITD/+; Stat5Δ/Δ 
- P = 0.0, FDR = 0.003, NES = 1.9
- Flt3ITD/+ vs. Flt3ITD/+; Stat5Δ/Δ 
- P = 0.0, FDR = 0.003, NES = 1.9

**E**
- IFN/IL receptor activity
- P = 0.0, FDR = 0.008, NES = -1.8
- Cytokine binding
- P = 0.0, FDR = 0.005, NES = -1.8
- Interferon gamma signaling
- P = 0.017, FDR = 0.087, NES = -1.8
Figure 8

A. Heatmap showing the expression levels of Ctsg and Socs2 in E14.5, P0, P14, and Adult stages in Wild type and Flt3 ITD/+ conditions. Ctsg expression is STAT5-independent, while Socs2 expression is STAT5-dependent.

B. Graphs showing the expression levels of Ctsg and Socs2 in different genotypes and stages. The expression levels are given in units.

C. Heatmap showing the expression levels of various genes in HSC and HPC across different stages. The expression levels are given in Row Z-score.

D. Graphs showing the expression levels of Lin28b and Esr1 in HSC and HPC across different stages. The expression levels are given in units.

E. 3D scatter plot showing the Euclidean distances and p values for different comparisons:
- E14.5 to P0 < P0 to Adult: < 0.03
- P14 to Adult < E14.5 to P14: < 0.03
- E14.5 to P0 < E14.5 to P14: < 0.02
- P14 to Adult < P0 to Adult: < 0.02
Figure 9

A) Differential gene expression between wt and Flt3ITD/+; RunxΔ/+. Differently expressed genes (adj. p<0.05 and FC≥3).

B) Gene expression changes in Flt3ITD/+; RunxΔ/+ (upregulated and downregulated).

C) Heatmap showing gene expression changes in different conditions.

D) Comparison of gene expression changes between different conditions.

E) Gene expression changes related to mTOR inhibition and apoptosis.
Figure 4 - figure supplement 1

A

<table>
<thead>
<tr>
<th>HSC/HPC</th>
<th>P-STAT5</th>
<th>P-AKT (S473)</th>
<th>P-AKT (T308)</th>
<th>Total AKT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLT3 ITD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pten Δ/Δ</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pten/Rictor Δ/Δ</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

HSCs (%)

<table>
<thead>
<tr>
<th>Flt3 genotype</th>
<th>+/+</th>
<th>ITD/ITD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rictor +/+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rictor Δ/Δ</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

Spleen weight (mg)

<table>
<thead>
<tr>
<th>Flt3 genotype</th>
<th>+/+</th>
<th>ITD/ITD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rictor +/+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rictor Δ/Δ</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 5 - figure supplement 1

HPC

<table>
<thead>
<tr>
<th></th>
<th>P-STAT5 (Y694)</th>
<th>Total STAT5</th>
<th>P-ERK1/2 (T202/Y204)</th>
<th>Total ERK1/2</th>
<th>β-ACTIN</th>
<th>PD0325901</th>
</tr>
</thead>
<tbody>
<tr>
<td>-/+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+/+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITD/+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- HPC:
- P-STAT5 (Y694)
- Total STAT5
- P-ERK1/2 (T202/Y204)
- Total ERK1/2
- β-ACTIN
- PD0325901
<table>
<thead>
<tr>
<th>Row Z-score</th>
<th>+/+</th>
<th>ITD/+</th>
<th>ITD/ITD</th>
<th>ITD/+</th>
<th>ITD/+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stat5a/b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fto1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ctsq</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Il18r1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Csf2rb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rasgrf2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gimap4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Camk2b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sparc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sparc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cdc64</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nhs12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gifr704</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyc10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miso2a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sf1n2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adams17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adams17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lrp12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cox16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hmga2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mboat2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cish</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rgs7bp</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mycn</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pldsc2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Klf9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Traf13os</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nhs12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tgm1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cx220840</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soc2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soc4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soc5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zfp352</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D430019H16Rik</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rab44</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rgcc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serpina3f</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bcl6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Temapl</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pdgfrb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tmem121</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tmem121</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Setr2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mnl</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tcl1614758</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cd33</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wdfc18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wdfc17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mshr3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dusp6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ddx4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cd52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ccr9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cox6a2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hlx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pld3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pcp411</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osgin1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hnf4a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goh1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ephn7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slc15a2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gaste</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 7 - figure supplement 1
Figure 8 - figure supplement 1
Figure 8 - figure supplement 2

<table>
<thead>
<tr>
<th>Euclidean distances</th>
<th>p values</th>
</tr>
</thead>
<tbody>
<tr>
<td>E14.5 to P0 &lt; P0 to Adult</td>
<td>&lt; 0.02</td>
</tr>
<tr>
<td>P14 to Adult &lt; E14.5 to P14</td>
<td>&lt; 0.02</td>
</tr>
<tr>
<td>E14.5 to P0 &lt; E14.5 to P14</td>
<td>&lt; 0.03</td>
</tr>
<tr>
<td>P14 to Adult &lt; P0 to Adult</td>
<td>&lt; 0.03</td>
</tr>
</tbody>
</table>